Compare · EIKN vs EXEL
EIKN vs EXEL
Side-by-side comparison of Eikon Therapeutics Inc. (EIKN) and Exelixis Inc. (EXEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EIKN and EXEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- EXEL is the larger of the two at $16.06B, about 62.3x EIKN ($257.9M).
- EXEL has been more active in the news (9 items in the past 4 weeks vs 7 for EIKN).
- EXEL has more recent analyst coverage (25 ratings vs 7 for EIKN).
- Company
- Eikon Therapeutics Inc.
- Exelixis Inc.
- Price
- -
- -
- Market cap
- $257.9M
- $16.06B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2000
- News (4w)
- 7
- 9
- Recent ratings
- 7
- 25
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Latest EIKN
- Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
- SEC Form 10-Q filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
- Eikon Therapeutics to Participate in Multiple Investor Conferences in November
- SEC Form 8-K filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
- SEC Form 8-K filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Latest EXEL
- FDA Approval for CABOMETYX issued to EXELIXIS INC
- FDA Approval for COMETRIQ issued to EXELIXIS
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form SCHEDULE 13G filed by Exelixis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Exelixis Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- SEC Form 10-Q filed by Exelixis Inc.
- SEC Form 8-K filed by Exelixis Inc.
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026